Higher-risk patients include those in the dose-escalation phase, those with nausea, vomiting, bloating, abdominal pain, early satiety, or reflux symptoms, those on higher doses with GI side effects, and those with known gastroparesis or other conditions that slow gastric emptying
Some individuals may present with nonspecific symptoms such as increased fatigue, confusion (particularly in older adults), or worsening glycemic control without classic urinary symptoms
Moreover, compound C was used to investigate whether AMPK pathway was also involved in the combined effect of metformin and liraglutide on the protein levels of GLP-1R and p-PKA
Lpidos en ayuno y postprandial: Semaglutida comparada con placebo, redujo las concentraciones de triglicridos y colesterol de lipoprotenas de muy baja densidad (VLDL) en ayuno en 12% y 21% respectivamente